价格

ApcinteX Ltd.

ACTIVE

英国www.apcintex.comSubsidiary1–10 名员工成立于: 2014-06-16

隶属于 Centessa Pharmaceuticals

概览

试验阶段分布

阶段

试验数

占比

2 期

28.6%

不适用

14.3%

1 期

14.3%

3 期

14.3%

试验状态分布

已完成

14.3%

尚未招募

28.6%

终止

57.1%

药物批准

暂无批准数据

资讯

Hemophilia B Therapeutics: Advances in Clinical Trials and Emerging Therapies

- Several companies are actively involved in developing therapies for Hemophilia B, with Belief Biomed's drug candidates reaching Phase III clinical trials. - Recent trials include Novo Nordisk's assessment of Nonacog Beta Pegol in Chinese patients and ApcinteX Ltd's study of SerpinPC in severe Hemophilia A or B. - Emerging therapies like BBM-H901 (Belief Biomed) and Fidanacogene elaparvovec (Pfizer/Spark Therapeutics) are under investigation across various clinical stages. - Hemophilia B therapies are being developed using various routes of administration, including oral, intravenous, and subcutaneous, and molecule types, such as gene therapy and recombinant fusion proteins.

Nov 28, 2024

返回机构列表

ApcinteX Ltd.

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（7）

The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

A Study of SerpinPC in Participants With Hemophilia B (HemB) With Inhibitors

The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Non-interventional Study to Evaluate Bleeding Episodes and Treatment Use in Patients with Hemophilia

Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)

The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B)

on-interventional Study to Evaluate Bleeding Episodes and Treatment Use in Patients with Hemophilia

药物批准

资讯

Hemophilia B Therapeutics: Advances in Clinical Trials and Emerging Therapies